



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 February 2015
EMA/27943/2015
Press Office

Guidelines and concept papers

Adopted during the CHMP meeting 23-26 February 2015

The guidelines and concept papers which have been adopted during this meeting of the Committee for Medicinal Products for Human Use (CHMP) will be published shortly on the European Medicines Agency's website under [Regulatory/Human/Scientific guidelines](#). Documents for public consultation will also be available under [Document search/Public consultations](#).

Quality Working Party

| Reference number | Document | Status |
|--------------------------------|---|--|
| EMA/96664/2015 | Draft Guideline on the Chemistry of Active Substances | Adopted for 6-months public consultation |
| EMA/CHMP/CVMP/QWP/776 887/2014 | Question-and-answer document on plastic containers for eye drops | Adopted |
| EMA/CHMP/QWP/104928/2 015 | Question-and-answer document on the calculation of thresholds to set limits for impurities in the finished product specification | Adopted |
| EMA/CHMP/QWP/558185/2 014 | Concept paper on the development of a guideline on quality and equivalence of topical products | Adopted for 3-months public consultation |
| EMA/CHMP/QWP/126334/2 015 | Concept paper on the need for Revision of the Guideline on the Requirements to the Chemical and Pharmaceutical Quality Documentation concerning Investigational Medicinal Products in Clinical Trials | Adopted for 3-months public consultation |
| EMA/CHMP/QWP/104223/2 015 | Reflection paper on the chemical structure and properties criteria to be considered for the evaluation of New Active Substance (NAS) status of chemical substances | Adopted for 3-months public consultation |



Vaccines Working Party

| Reference number | Document | Status |
|------------------|--|---------|
| EMA/695450/2014 | Work plan for the Vaccines Working Party (VWP) | Adopted |

Biostatistics Working Party

| Reference number | Document | Status |
|----------------------|--|---------|
| EMA/801811/2014 | Work plan for the Biostatistics Working Party | Adopted |
| EMA/CHMP/295050/2013 | Guideline on adjustment for baseline covariates in clinical trials | Adopted |

Blood Products Working Party

| Reference number | Document | Status |
|----------------------------------|--|---------|
| EMA/CHMP/BPWP/517446/2014 | CHMP Blood Products Working Party (BPWP) Work programme 2015 | Adopted |
| EMA/CHMP/BPWP/143744/2011 rev. 1 | Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration | Adopted |

Oncology Working Party

| Reference number | Document | Status |
|------------------|---|--|
| EMA/130525/2015 | Concept paper on the need to revise the "Guideline on the evaluation of anticancer medicinal products in man" in order to provide guidance on the reporting of safety data from clinical trials | Adopted for 3-months public consultation |

Biosimilar Medicinal Product Working Party

| Reference number | Document | Status |
|---------------------------------|--|---------|
| EMA/CHMP/BMWP/32775/2005 Rev. 1 | Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues | Adopted |

Cardiovascular Working Party

| Reference number | Document | Status |
|---------------------------|---|--|
| EMA/CHMP/41230/2015 Rev.1 | Draft Guideline on clinical investigation of medicinal products for the treatment of venous thromboembolic disease | Adopted for 6-months public consultation |
| EMA/CHMP/206815/2013 | Paediatric Addendum to the Note for Guidance on Clinical Investigation of Medicinal Products in the Treatment of Hypertension | Adopted |

Rheumatology/Immunology Working Party

| Reference number | Document | Status |
|---------------------|---|--|
| EMA/CHMP/80184/2015 | Concept paper on clinical investigation of medicinal products for the treatment of Axial Spondyloarthritis | Adopted for 3-months public consultation |
| EMA/CHMP/51230/2013 | Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis | Adopted |

Excipients Labelling Drafting Group

| Reference number | Document | Status |
|----------------------|---|---------|
| EMA/CHMP/495737/2013 | Questions and answers on benzalkonium chloride in the context of the revision of the guideline on 'Excipients in the label and package leaflet of medicinal products for human use' | Adopted |

Modelling and Simulation Working Group

| Reference number | Document | Status |
|------------------|--|---------|
| EMA/91751/2015 | EMA Modelling and Simulation Working Group Plan 2015 | Adopted |